Transfusion associated graft versus host disease
JAMC-Journal of Ayub Medical College-Abbotabad-Pakistan. 2003; 15 (3): 56-58
in English
| IMEMR
| ID: emr-62382
ABSTRACT
Transfusion associated graft versus host disease [TA-GVHD] results from engraftment of viable donor T-lymphocytes in recipient that can not recognize or destroy them. It is seen in immunocompromised patients and pre-mature neonates. It can also occur in immunocompetent individuals receiving blood from first-degree relatives. It has emerged as single most common cause of death resulting from transfusion. Patients with B-cell malignancies appear to be especially at risk. TA-GVHD is associated with 80-90% mortality. Death most commonly occurs due to infection or haemorrhage secondary to pancytopenia. It is therefore important to prevent its occurrence. Prevention can be achieved either by complete removal of T-lymphocytes from donors blood or by abolishing their proliferating potentials. Available methods of leuko-depletion are not effective in preventing TA-GVHD. Only effective way is to inactivate T-lymhocytes. This can be achieved by irradiating blood product with gamma or X-ray irradiation. The concerns about malignant transformation of cells or reactivation of intracellular viruses have not been proved so far. Newer technologies for T-cell inactivation, which are not based on irradiation, are currently under trial. This is a review article
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Blood Transfusion
/
T-Lymphocytes
/
Immunocompromised Host
Language:
English
Journal:
J. Ayub Med. Coll.-Abbotabad-Pak.
Year:
2003
Similar
MEDLINE
...
LILACS
LIS